CRX 527 

CRX 527 is a ligand of TLR4 and also serves as an adjuvant for peptide-based cancer vaccines, showing potential to enhance anti-tumor immune responses. CRX 527 can also induce HSC differentiation, increase the proportion and quantity of LSK cells, and promote their differentiation into macrophages, activating immune defense and protecting intestinal epithelium from radiation damage^[1][2].

1488.04

C₈₁H₁₅₁N₂O₁₉P

216014-14-1

CCCCCCCCCC(O[C@H](CCCCCCCCCCC)CC(O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1OP(O)(O)=O)CO)OC[C@@H](C(O)=O)NC(C[C@@H](CCCCCCCCCCC)OC(CCCCCCCCC)=O)=O)NC(C[C@@H](CCCCCCCCCCC)OC(CCCCCCCCC)=O)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Dongshu Liu, et al. CRX-527 induced differentiation of HSCs protecting the intestinal epithelium from radiation damage. Front Immunol. 2022 Aug 30;13:927213.

  [2]. Elena Tondini, et al. Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control. NPJ Vaccines. 2022 Jun 23;7(1):64.